Individual Patient TCR-Transduced PBL

AUG 13, 2026 · PHASE 2 TRIAL

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

ClinicalTrials.gov

This is a Phase 2 interventional trial registration with no results yet posted; it describes planned enrollment and study design only, making it an early-stage assessment of a novel cell therapy approach.